Paediatric Cystic Fibrosis (CF) 2021
DOI: 10.1183/13993003.congress-2021.pa2101
|View full text |Cite
|
Sign up to set email alerts
|

The impact of Symkevi (Tezacaftor/Ivacaftor) on exercise capacity in adolescents with CF

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Ivan Bambir (Zagreh, Croatia) reported a significant improvement in exercise tolerance in 12pwCF (range 12-18 years) using the 6minute walk test upon ≥ 6 months of treatment with ELX/TEZ/IVA [32]. Molla Imadudin Ahmed (Leicester, UK) analysed the impact of ELX/TEZ/IVA on exercise capacity by cardiopulmonary exercise testing at baseline and after 6-8 months without detecting changes in VO2 peak in a cohort of 7 pwCF [33].…”
Section: Paediatric Cystic Fibrosismentioning
confidence: 99%
“…Ivan Bambir (Zagreh, Croatia) reported a significant improvement in exercise tolerance in 12pwCF (range 12-18 years) using the 6minute walk test upon ≥ 6 months of treatment with ELX/TEZ/IVA [32]. Molla Imadudin Ahmed (Leicester, UK) analysed the impact of ELX/TEZ/IVA on exercise capacity by cardiopulmonary exercise testing at baseline and after 6-8 months without detecting changes in VO2 peak in a cohort of 7 pwCF [33].…”
Section: Paediatric Cystic Fibrosismentioning
confidence: 99%